Your browser doesn't support javascript.
loading
MSMO1 deficiency: a potentially partially treatable, ultrarare neurodevelopmental disorder with psoriasiform dermatitis, alopecia and polydactyly.
Tkemaladze, Tinatin; Bratland, Eirik; Bregvadze, Kakha; Shatirishvili, Teona; Tatishvili, Nino; Abzianidze, Elene; Houge, Gunnar; Douzgou, Sofia.
Afiliación
  • Tkemaladze T; Department of Molecular and Medical Genetics, Tbilisi State Medical University.
  • Bratland E; Department of Child Neurology, M. Iashvili Children's Central Hospital, Tbilisi, Georgia.
  • Bregvadze K; Department of Medical Genetics, Haukeland University Hospital.
  • Shatirishvili T; Department of Clinical Science, University of Bergen, Bergen, Norway.
  • Tatishvili N; Department of Molecular and Medical Genetics, Tbilisi State Medical University.
  • Abzianidze E; Department of Child Neurology, M. Iashvili Children's Central Hospital, Tbilisi, Georgia.
  • Houge G; Department of Child Neurology, M. Iashvili Children's Central Hospital, Tbilisi, Georgia.
  • Douzgou S; Department of Molecular and Medical Genetics, Tbilisi State Medical University.
Clin Dysmorphol ; 32(3): 97-105, 2023 Jul 01.
Article en En | MEDLINE | ID: mdl-37195326
ABSTRACT
MSMO1 deficiency (OMIM #616834) is an ultrarare autosomal recessive disorder of distal cholesterol metabolism with only five cases reported to date. The disorder is caused by missense variants in the MSMO1 gene encoding methylsterol monooxygenase 1, leading to the accumulation of methylsterols. Clinically, MSMO1 deficiency is characterized by growth and developmental delay, often in association with congenital cataracts, microcephaly, psoriasiform dermatitis and immune dysfunction. Treatment with oral and topical cholesterol supplements and statins was reported to improve the biochemical, immunological, and cutaneous findings, supporting a potential treatment following the precision diagnosis of MSMO1 deficiency. We describe two siblings from a consanguineous family presenting with novel clinical features of polydactyly, alopecia and spasticity. Whole-exome sequencing revealed a novel, homozygous c.548A > C, p.(Glu183Ala) variant. Based on previously published treatment algorithms, we initiated a modified dosage regime with systemic cholesterol supplementation, statins and bile acid along with topical application of a cholesterol/statin formulation. This resulted in a marked improvement of psoriasiform dermatitis and some hair growth.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polidactilia / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Dermatitis / Trastornos del Neurodesarrollo / Microcefalia Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Dysmorphol Asunto de la revista: TERATOLOGIA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polidactilia / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Dermatitis / Trastornos del Neurodesarrollo / Microcefalia Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Dysmorphol Asunto de la revista: TERATOLOGIA Año: 2023 Tipo del documento: Article
...